CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 724 enrolled
Drug / intervention
dexamethasone 700 ㎍ intravitreal implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01976650
NCT01976650N/ACompleted
CompareCT.gov

Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea

Allergan·observational·Posted Nov 6, 2013·Updated Jan 13, 2016

In Brief

An observational study evaluating dexamethasone 700 ㎍ intravitreal implant for Retinal Vein Occlusion. Completed, enrolled 724 participants across 1 site.

Detailed Summary

This study is a Post-Market Surveillance study in Korea to evaluate the safety and efficacy of dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant used to treat Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye in clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 6, 2013
Enrollment StartMar 1, 2011
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 12.7 years ago

Interventions

dexamethasone 700 ㎍ intravitreal implantdrug

dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.